News

Latest news

Hide mandatory notifications of trade

Approved supplemental prospectus

26.02.2010 - Oslo Børs has approved following supplemental prospectus:NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

Oslo Børs has approved following supplemental
prospectus:

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR
IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

Supplemental prospectus

Nutri Pharma ASA
(Registration number: 966 033 967)
www.nutripharma.com

Offering and listing of up to 10,000,000 Subsequent
Offering Shares each with a nominal value of NOK 0.25
in connection with a repair offering to Eligible
Shareholders at a subscription price of NOK 2.00
raising total gross proceeds of up to NOK 20,000,000.

Subscription period from 19 February 2010 to and
including 4 March 2010.

THE SUBSEQUENT OFFERING SHARES HAVE NOT BEEN AND WILL
NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF
1933, AS AMENDED. SEE "RISK FACTORS" IN SECTION 2 FOR
A DISCUSSION OF CERTAIN MATTERS THAT SHOULD BE
CONSIDERED IN CONNECTION WITH AN INVESTMENT IN THE
SUBSEQUENT OFFERING SHARES.

Listing of 50,000,000 Private Placement Shares on
Oslo Børs ASA, each with a nominal value of NOK 0.25
in connection with the Private Placement at a
subscription price of NOK 2.00 raising total gross
proceeds of NOK 100,000,000. These shares are not
offered or sold pursuant to this Prospectus.

Listing of 43,889,262 Offer Shares on Oslo Børs ASA,
each with a nominal value of NOK 0.25 issued in a
private placement at a subscription price of NOK 1.83
per share in connection with the all share offer for
Bionor Immuno AS. These shares are not offered or
sold pursuant to this Prospectus.

Pareto Securities AS
Lead Manager and Bookrunner of the Private Placement
and sole manager of the Subsequent Offering

The prospectus is available to the public at:

Pareto Securites AS: [http://www.pareto.no]
Nutri Pharma ASA: [http://www.nutripharma.no]

25 February 2010